StockNews.com Begins Coverage on Oragenics (NYSE:OGEN)

StockNews.com began coverage on shares of Oragenics (NYSE:OGEN) in a note issued to investors on Monday. The firm set a “sell” rating on the stock.

Oragenics Stock Up 0.5 %

OGEN stock opened at $0.27 on Monday. Oragenics has a 52-week low of $0.25 and a 52-week high of $3.43. The stock’s fifty day simple moving average is $0.32 and its 200-day simple moving average is $0.46. The stock has a market capitalization of $3.34 million, a price-to-earnings ratio of -0.04 and a beta of 0.38.

Oragenics Company Profile

Oragenics, Inc, a development-stage company, engages in the research and development of antibiotics for infectious diseases in the United States. The company engages in the development and commercialization of NT-CoV2-1, an intranasal vaccine candidate that provides immunity from the novel severe acute respiratory syndrome coronavirus.